Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669810 | 0.83 | GAA (0.42) | GAAMAPK8MAPK9MAPK10ALDH1A1 | |
| SCHEMBL13106381 | 0.80 | GAA (0.40) | GAAMAPK8MAPK9MAPK10ALDH1A1 | |
| SCHEMBL13106356 | 0.78 | ESR1 (0.43) | MAPK8MAPK9MAPK10ALDH1A1MAPK1 | |
| SCHEMBL13106366 | 0.73 | MAPK8 (0.36) | GAAMAPK8MAPK9MAPK10ALDH1A1 | |
| SCHEMBL13106438 | 0.71 | MAPK8 (0.43) | GAAMAPK8MAPK9MAPK10 | |
| SCHEMBL13106445 | 0.70 | MAPK8 (0.42) | GAAMAPK8MAPK9MAPK10ALDH1A1 | |
| SCHEMBL13106383 | 0.70 | MAT2A (0.33) | MAT2A | |
| SCHEMBL13106436 | 0.69 | MAPK8 (0.36) | GAAMAPK8MAPK9MAPK10HTR2A | |
| SCHEMBL13106360 | 0.69 | MAPK8 (0.36) | GAAMAPK8MAPK9MAPK10CYP2C9 | |
| SCHEMBL23870234 | 0.68 | PIM1 (0.34) | GAAALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | GAA 55/4885MAPK8 3107/4885MAPK9 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.